Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.

Détails

ID Serval
serval:BIB_56B88CB4B0A0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency.
Périodique
European Journal of Gastroenterology and Hepatology
Auteur⸱e⸱s
Barth F., Gerber P.J., Reichen J., Dufour J.F., Nicod L.P.
ISSN
0954-691X[print], 0954-691X[linking]
Statut éditorial
Publié
Date de publication
2006
Volume
18
Numéro
10
Pages
1117-1119
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Résumé
Bosentan has lately been described as a successful therapeutic agent for portopulmonary hypertension consecutive to child A cirrhosis. This is the first report of the effect of this substance with advanced liver cirrhosis (child C) and renal insufficiency. Low doses of bosentan (initially twice 31.25 mg/day and then 62.5 mg/day) increased cardiac output and allowed correction of renal insufficiency; it allowed one to stop the requirement of oxygen and not only improved the 6-min walking test by more than 400 m, but also decreased the severity of the liver cirrhosis to child B stadium. This suggests that patients, who would be excluded from a liver transplantation program because of their portopulmonary hypertension, could profit from a careful therapy with bosentan.
Mots-clé
Adult, Antihypertensive Agents/therapeutic use, Humans, Hypertension, Portal/drug therapy, Hypertension, Portal/etiology, Hypertension, Pulmonary/drug therapy, Hypertension, Pulmonary/etiology, Liver Cirrhosis/complications, Male, Renal Insufficiency/complications, Sulfonamides/therapeutic use, Treatment Outcome
Pubmed
Web of science
Création de la notice
19/02/2010 20:19
Dernière modification de la notice
20/08/2019 15:10
Données d'usage